Shots:

• Mestag to receive option fees- milestones- royalties and will deploy its specialist fibroblast sub-population biology platform and state-of-the-art data analytics to identify novel therapeutic targets
• Janssen to get an option to exclusive license to develop and commercialize therapies directed against up to two targets emerges from the collaboration
• Apart from this collaboration- Mestag will continue to develop its inflammatory disease and cancer programs as it progresses its pipeline of first-in-class therapeutics towards the clinic

  Ref: Mestag Therapeutics | Image: Janssen